EULAR 2025 highlights… EULAR 2025 Highlights – SLE and APS 18 Jul 2025 Preliminary results of CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosus-an open-label, single-arm study Abstract format and assignment number: Oral presentation OP0074 Date: Wednesday, 11…
EULAR 2025 highlights… EULAR 2025 Highlights – Other Connective Tissue Diseases and Vasculitis 18 Jul 202522 Jul 2025 EFFICACY AND SAFETY OF EFGARTIGIMOD PH20 SC IN ADULT PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHY: PHASE 2 RESULTS FROM THE ALKIVIA STUDY Abstract format and assignment number: Oral presentation OP0002 Date: Wednesday,…
EULAR 2025 highlights… EULAR 2025 Highlights – Metabolic and Crystal arthropathies 18 Jul 2025 Genakumab reduces the risk of acute gout flares during initiation of urate-lowering therapy: A phase 2, randomized, open-label, multi-center, active-controlled clinical trial Abstract format and assignment number: Oral presentation OP0299…